At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Not specified by the sponsor
- How long the study runs
- Study runs about 17 months (dates as stated)
- About the drug or intervention
- Not specified by the sponsor
- Patient visit burden
- Not specified by the sponsor
In plain English
This study, called MIDSECTION, is looking at whether it is possible to use MRI (magnetic resonance imaging, a scan that uses magnets instead of X-rays) to guide a type of precise high-dose radiotherapy called stereotactic ablative radiotherapy (SABR). It is for people with cancer in the abdomen (the area of the body between the chest and hips) or lung cancer. It is sponsored by The Christie NHS Foundation Trust.
Who can take part
- You are able to have MRI scans (nothing rules them out for you).
- You can have SABR to the abdomen under NHS England SABR Consortium Guidelines, or SABR to the central lung under RTOG Guidelines.
- You are able to give informed consent (agree to take part after being told about the study).
- You are expected to live more than 6 months.
- You have no more than 3 sites of spread (oligometastatic disease) being treated in total.
- Your day-to-day activity level (performance status) is 2 or better.
- You are willing to go to follow-up appointments and let the team collect your details for at least 1 year.
Who may not be able to
- Anything found on the MRI safety screening form that means you cannot have MRI scans.
- You cannot tolerate MRI scans.
- You have a severe or uncontrolled illness that, in the study team's view, makes taking part unwise.
- You have a significant health condition or test result that, in the study team's view, makes taking part unwise.
- You have active hepatitis B, hepatitis C, or HIV.
What taking part involves
- • MRI-guided stereotactic ablative radiotherapy (SABR), which is a precise, high-dose form of radiotherapy.
- • Not stated — ask the trial team about the exact treatment plan.
Time commitment: You would attend follow-up appointments and have your details collected for at least 1 year; other details about visits and duration are not stated — ask the trial team.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 60
- Started
- 2025-08-29
- Last checked
- 2025-08
Plain English Summary
What is this study?
- • Testing a new treatment for abdominal cancer
- • Clinical study - 60 participants
- • To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with abdominal cancer
Where?
- • Manchester - The Christie NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.
More detail
Stereotactic Ablative Radiotherapy (SABR) for tumours in the thorax and abdomen is becoming the standard of care for patients with small, localised disease. Recent publications and guidelines provide evidence for safe, effective treatment prescriptions in most of these tumour sites. However this guidance is based on the use of x-ray based guidance systems, without the use of functional imaging or real-time adaptation. To investigate the potential benefits of MRI-guided SABR, including superior at-treatment imaging, gating, real-time adaptation and the integration of functional or biological information, the investigators propose to undertake MR-guided SABR using established guidance. In doing this the investigators will be able to evaluate the patient experience (for example the MR Linac is considerably noisier than a standard treatment machine); the investigators will be able to acquire images (with no additional radiation) to interrogate motion, and deformations in real-time to assess whether or not real time adaptations would benefit the patient experience and/or outcomes; the investigators will be able to compare the outcomes of the patients treated on a machine with superior imaging to those undergoing the same (or similar) treatment on standard machines using the UKCAT database; the investigators will be able (should participants choose to give consent) to acquire research images interrogating tumour and normal tissue physiology/biology and determine if and how this information may be able to improve treatments and/or predict response. For these reasons it is important to make this change in practice (from x-ray guided SABR to MRI-guided SABR) within the confines of an observational clinical study.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Have no MRI contra-indications.
- ✓Eligible for abdominal SABR in accordance with the NHSE SABR Consortium Guidelines or eligible for central lung SABR...
- ✓Be able to give agreement to take part.
- ✓Anticipated life-expectancy \> 6 months.
- ✓Not more than 3 oligmetastatic sites treated in total per patients.
Who cannot take part
- ✗Any contraindications to MRI identified after MRI safety screening including completion of an MRI Safety Screening Form.
- ✗Unable to tolerate MRI scans.
- ✗Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator make it undesirable...
- ✗Any evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator, make...
- ✗Any patient known to have active hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
See the full criteria
Where Is This Study? (1 UK site)
The Christie NHS Foundation Trust
Manchester M204BX, United Kingdom
How to Get in Touch
Clare Griffin
Sponsor contactCONTACT
Cynthia Eccles
Sponsor contactCONTACT